references/endpoint_and_power.md
Endpoints and Statistical Power
Reference for endpoint selection and sample-size estimation. Pairs with endpoint_selector.py and sample_size_estimator.py.
Endpoint hierarchy
- Clinical outcome — directly measures how a patient feels, functions, or survives (mortality, stroke, symptom resolution). Strongest regulatory standing.
- Surrogate endpoint — a biomarker intended to substitute for a clinical outcome (LDL cholesterol, viral load, tumor response). Only acceptable if validated for the specific indication. FDA maintains a public Surrogate Endpoint Table listing surrogates that have supported approvals; the BEST glossary defines the validation hierarchy (candidate → reasonably likely → validated).
- Patient-reported outcome (PRO) — measured directly from the patient via a validated instrument. FDA's 2009 PRO guidance sets the bar for instrument validity, reliability, and content validity.
The tool penalizes an unvalidated surrogate so it cannot anchor a PRIMARY endpoint — this mirrors the regulatory reality that an unvalidated surrogate carries approval risk.
Choosing the effect size (the hardest input)
The single most consequential — and most abused — input is the assumed effect size. It must be clinically meaningful and externally justified, never reverse-engineered from the n you can afford.
- For means, the effect is Cohen's d (standardized mean difference). Cohen's conventional small/medium/large (0.2 / 0.5 / 0.8) are last resorts, not anchors — prefer a published or anchor-based MCID.
- For proportions, specify the control and treatment rates from prior data; the absolute difference drives n.
- For survival, specify the target hazard ratio; required events (not patients) drive power via Schoenfeld's approximation, then n follows from the overall event probability.
Power formulas the tool implements
- Two-sample means: n_per_arm = 2·((z_α + z_β)/d)², adjusted for allocation ratio k.
- Two-sample proportions: n = [z_α·√(2·p̄·q̄) + z_β·√(p₁q₁ + p₂q₂)]² / (p₁ − p₂)².
- Survival (Schoenfeld): required events E = 4·(z_α + z_β)² / (ln HR)²; n = E / P(event).
All inflate for dropout by 1/(1 − dropout). These are estimates; a biostatistician produces the binding justification, possibly via simulation.
Sources
- Cohen, J., Statistical Power Analysis for the Behavioral Sciences, 2nd ed. (1988).
- Schoenfeld, D., Sample-size formula for the proportional-hazards regression model — Biometrics 1983;39:499-503.
- Chow, Shao, Wang & Lokhnygina, Sample Size Calculations in Clinical Research, 3rd ed. (CRC, 2017).
- FDA, Surrogate Endpoint Resources for Drug and Biologic Development (public Surrogate Endpoint Table).
- FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) Resource glossary (2016, updated).
- FDA, Patient-Reported Outcome Measures: Use in Medical Product Development (2009).
- Fleming & DeMets, Surrogate end points in clinical trials: are we being misled? — Ann Intern Med 1996;125:605-613.